Vaccine

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for BetacoronavirusesEmergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

First-in-human intradermal administration of CoronaTcP™ was generally well-toleratedEvidence for generation of virus-specific effector and memory CD8+ T cellsData reinforce findings…

2 years ago
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec HealthRelief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health

Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE®GENEVA, SWITZERLAND / ACCESSWIRE /…

2 years ago
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with OranoDefence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…

2 years ago
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch ActivitiesBlue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology…

2 years ago
Phreesia Acquires MediFind, Reinforcing its Commitment to Patient-Centered Care and Expanding its Offerings to ConsumersPhreesia Acquires MediFind, Reinforcing its Commitment to Patient-Centered Care and Expanding its Offerings to Consumers

Phreesia Acquires MediFind, Reinforcing its Commitment to Patient-Centered Care and Expanding its Offerings to Consumers

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has acquired Comsort, Inc.…

2 years ago
POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 TrialPOP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

BUFFALO, NY / ACCESSWIRE / July 14, 2023 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top…

2 years ago
CureVac Announces Update to the Management TeamCureVac Announces Update to the Management Team

CureVac Announces Update to the Management Team

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

2 years ago
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property RightsCureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rightsThree new intellectual property rights added to…

2 years ago
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics…

2 years ago